IFNL3 and cryohydrocytosis: IL28B genotype is the predictor for non-responder in GT-1 CHC patients treated with PegIFN/RBV, while baseline serum level of CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype.